(See notice at the end of this document regarding copyright.) This site is for those who know nothing of R, and maybe even nothing of programming, and seek QUICK, PAINLESS! entree to the world of R.
Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program. The alliance ...
Instead, the company plans to focus on ‘world-class first-party hardware and software.’ Instead, the company plans to focus on ‘world-class first-party hardware and software.’ is a senior reporter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback